BioMarin Pharma (BMRN) Tops Q3 EPS by 6c
Get Alerts BMRN Hot Sheet
EPS Growth %: -45.0%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
CPSS, HARL, MCET, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $176.8 million versus the consensus estimate of $206 million.
As of September 30, 2014, BioMarin had cash, cash equivalents and investments totaling $1,114.7 million, as compared to $1,052.4 million on December 31, 2013.
"The commercial launch of VIMIZIM continues to make excellent progress. We are extremely pleased with the success of the U.S. launch and the progress we are making in the European Union seeking reimbursement for VIMIZIM on a country by country basis," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "In addition, our more established commercial portfolio continues to grow, with both Naglazyme and Kuvan growing approximately 20% during the first three quarters of this year compared to last year. We believe that the continued growth of our five commercial products will help BioMarin reach over $1 billion in revenues over the next 2-3 years."
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equifax (EFX) shares tumble as Q2, full-year guidance falls short
- Cohen & Steers (CNS) Misses Q1 EPS by 2c
- First Industrial Realty (FR) Tops Q1 EPS by 21c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!